Join the PharmaShots Family of 20000+ Subscribers by PharmaShots

PharmaShots Oct 9, 2025

LIFE SCIENCES | DAILY NEWS | OCT 09, 2025 | PHARMASHOTS

The post LIFE SCIENCES | DAILY NEWS | OCT 09, 2025 | PHARMASHOTS appeared first on PharmaShots.

Read article →
PharmaShots Oct 9, 2025

Boehringer Ingelheim Reports the US FDA’s Approval of Jascayd (Nerandomilast) for Idiopathic Pulmonary Fibrosis

Shots: Ref: Boehringer Ingelheim| Image: Boehringer Ingelheim | Press Release Related News:- The NMPA Grants Conditional…

Read article →
PharmaShots Oct 9, 2025

Johnson & Johnson Reports P-III (ASTRO) Trial Data of SC Tremfya (Guselkumab) for Ulcerative Colitis (UC)

Shots: Ref: Johnson & Johnson | Image: Johnson & Johnson | Press Release Related News:- Johnson & Johnson’s Tremfya…

Read article →
PharmaShots Oct 9, 2025

AviadoBio Enters Exclusive Option & License Agreement with UgeneX Therapeutics to Advance UGX-202

Shots: Ref: AviadoBio | Image: AviadoBio & UgeneX Therapeutics | Press Release Related News:- Zenas BioPharma Enters…

Read article →
PharmaShots Oct 9, 2025

Bunkerhill Health Receives the US FDA’s 510(k) Clearance for Bunkerhill MAC to Detect and Quantify Mitral Annular Calcification

Shots: Ref: Bunkerhill Health | Image: Bunkerhill Health| Press Release Related News:- Hologic Secures the US FDA’s…

Read article →
PharmaShots Oct 9, 2025

Ascendis Pharma Reports the EMA’s MAA Submission for TransCon CNP to Treat Achondroplasia in Children

Shots: Ref: Ascendis Pharma | Image: Ascendis Pharma| Press Release Related News:- Ascendis Pharma’s Yorvipath…

Read article →
PharmaShots Oct 9, 2025

Regeneron Reports the US FDA’s Approval of Adjuvant Libtayo to Treat High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Shots: Ref: Regeneron | Image: Regeneron | Press Release Related News:- Regeneron’s Evkeeza Receives the US FDA’s…

Read article →
PharmaShots Oct 8, 2025

Top 20 Generic Pharma Companies of 2025 

Shots: Rank Companies Generic Revenue (2023 $B) Generic Revenue (2024 $B) Percent change (%) 1 Sandoz 9.64 10.35 7.36…

Read article →